146 related articles for article (PubMed ID: 28953642)
21. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
22. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Liang R; Yang L; Zhu X
Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
[TBL] [Abstract][Full Text] [Related]
23. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
25. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.
Huang S; He R; Rong M; Dang Y; Chen G
Biomed Res Int; 2014; 2014():384121. PubMed ID: 24895573
[TBL] [Abstract][Full Text] [Related]
27. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
[TBL] [Abstract][Full Text] [Related]
28. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Roviello G; Sohbani N; Petrioli R; Rodriquenz MG
Invest New Drugs; 2019 Dec; 37(6):1274-1288. PubMed ID: 30879152
[TBL] [Abstract][Full Text] [Related]
29. Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.
Jia J; Qi X; Bai W; Yuan J; Han G
J Cancer Res Ther; 2014; 10(4):1112-4. PubMed ID: 25579566
[TBL] [Abstract][Full Text] [Related]
30. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
31. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Liu D; Liu A; Peng J; Hu Y; Feng X
Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
[TBL] [Abstract][Full Text] [Related]
33. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
34. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Yao X; Wang L; Gao J
Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
[TBL] [Abstract][Full Text] [Related]
35. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
36. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
38. [Effects of cetuximab combined erlotinib on proliferation of human hepatocellular carcinoma cell lines HepG2 and Bel-7402].
Wei W; Guo RP; Li JQ; Xu L; Shi M; Zhang YQ
Ai Zheng; 2008 Apr; 27(4):386-92. PubMed ID: 18423125
[TBL] [Abstract][Full Text] [Related]
39. Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report.
Impellizzeri G; Renzulli M; Azzaroli F; Golfieri R; Mazzella G; Marasco G
J Gastrointestin Liver Dis; 2020 Nov; 30(1):142-146. PubMed ID: 33118539
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.
Fang P; Hu JH; Cheng ZG; Liu ZF; Wang JL; Jiao SC
PLoS One; 2012; 7(12):e49717. PubMed ID: 23284624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
